Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
暂无分享,去创建一个
E. Reddy | S. Baker | Shashidhar S Jatiani | E Premkumar Reddy | Stacey J Baker | Lewis R Silverman | L. Silverman | E. P. Reddy
[1] J. Griffin,et al. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl , 1996, The Journal of experimental medicine.
[2] H. F. Barker,et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. , 2005, Cancer research.
[3] E. Reddy,et al. A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. , 2010, Genes & cancer.
[4] O. Silvennoinen,et al. Signaling through the hematopoietic cytokine receptors. , 1995, Annual review of immunology.
[5] T. Shows,et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. , 1990, Oncogene.
[6] N. Danial,et al. Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.
[7] G. Stark,et al. The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction , 1993, Nature.
[8] T. Maiwald,et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF‐E2 , 2005, British journal of haematology.
[9] M. Wadleigh,et al. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors. , 2010, Clinical advances in hematology & oncology : H&O.
[10] E. Reddy,et al. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs , 1997, Molecular and cellular biology.
[11] S. Bohlander,et al. A BCR–JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia , 2005, Genes, chromosomes & cancer.
[12] J. Darnell. STATs and gene regulation. , 1997, Science.
[13] J. Wilson-Rawls,et al. P210 Bcr-Abl interacts with the interleukin-3 beta c subunit and constitutively activates Jak2. , 1997, Leukemia.
[14] S. Rane,et al. Hematopoietic cytokine receptor signaling , 2007, Oncogene.
[15] N. Copeland,et al. Distribution of the mammalian Stat gene family in mouse chromosomes. , 1995, Genomics.
[16] P. Brousset,et al. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation. , 2006, Human pathology.
[17] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[18] W. Vainchenker,et al. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. , 2008, Seminars in cell & developmental biology.
[19] V. Najfeld,et al. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. , 2007, Experimental hematology.
[20] W. Sanger,et al. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. , 2006, Experimental and molecular pathology.
[21] G. Yancopoulos,et al. The alphas, betas, and kinases of cytokine receptor complexes , 1993, Cell.
[22] T. Hunter. Cytokine connections , 1993, Nature.
[23] A. Tefferi,et al. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.
[24] W. Leonard,et al. Cloning of Human Stat5B , 1996, The Journal of Biological Chemistry.
[25] C. Sieff,et al. A low-affinity human granulocyte-macrophage colony-stimulating factor/murine erythropoietin hybrid receptor functions in murine cell lines. , 1993, Blood.
[26] S. Bhattacharya,et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.
[27] J. Cleveland,et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[28] I. Dusanter-Fourt,et al. The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). , 1997, European journal of biochemistry.
[29] Asim Khwaja,et al. The role of Janus kinases in haemopoiesis and haematological malignancy , 2006, British journal of haematology.
[30] O. Silvennoinen,et al. The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction* , 2002, The Journal of Biological Chemistry.
[31] S. Rane,et al. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. , 1994, Oncogene.
[32] T. Hunter. Signal transduction. Cytokine connections. , 1993, Nature.
[33] R. V. van Etten,et al. P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.
[34] Martin C. Müller,et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. , 2007, The Lancet. Oncology.
[35] S. Goff,et al. Direct Interaction of Jak1 and v-Abl Is Required for v-Abl-Induced Activation of STATs and Proliferation , 1998, Molecular and Cellular Biology.
[36] J. Renauld,et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. , 2009, Blood.
[37] Yi Lin Chen,et al. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. , 2010, American Journal of Clinical Pathology.
[38] A. Wilks,et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase , 1991, Molecular and cellular biology.
[39] K. Liedl,et al. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. , 2001, Protein engineering.
[40] H. Kantarjian,et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. , 2009, The Journal of molecular diagnostics : JMD.
[41] C. Schindler,et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. , 1993, Nature.
[42] A. Alcover,et al. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression , 2003, The EMBO journal.
[43] P. Heinrich,et al. Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. , 2002, The Biochemical journal.
[44] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[45] L. Varticovski,et al. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. , 1996, Leukemia.
[46] R. Kiss,et al. Recent developments on JAK2 inhibitors: a patent review , 2010, Expert opinion on therapeutic patents.
[47] P. Brousset,et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene , 2005, Oncogene.
[48] H. Lodish,et al. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization , 1994, Molecular and cellular biology.
[49] J. Tripodi,et al. A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). , 2009 .
[50] M. Fellous,et al. Specific Contribution of Tyk2 JH Regions to the Binding and the Expression of the Interferon α/β Receptor Component IFNAR1* , 1998, The Journal of Biological Chemistry.
[51] P. Heinrich,et al. The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak/STAT Signaling but Plays a Structural Role for Receptor Interaction and Up-regulation of Receptor Surface Expression* , 2005, Journal of Biological Chemistry.
[52] D. Birnbaum,et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation , 2005, Leukemia.
[53] Takamune Takahashi,et al. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases , 1994, FEBS letters.
[54] S. Kajigaya,et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. , 2004, Blood.
[55] P. Marynen,et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.
[56] P. Fenaux,et al. Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms , 2008, Leukemia.
[57] S. Akira,et al. Cytokine signal transduction , 1994, Cell.
[58] R. Siebert,et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2 , 2003, International journal of cancer.
[59] T. Taniguchi,et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[60] G. Stark,et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. , 1992, Cell.
[61] Yan Wang,et al. Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation , 2001, Oncogene.
[62] O. Silvennoinen,et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase , 1993, Cell.
[63] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[64] S. Verstovsek. Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis , 2010, Clinical Cancer Research.
[65] T. Hoey,et al. Cooperative DNA Binding and Sequence-Selective Recognition Conferred by the STAT Amino-Terminal Domain , 1996, Science.
[66] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[67] D. Gilliland,et al. Oncogenes in Myeloproliferative Disorders , 2007, Cell cycle.
[68] O. Silvennoinen,et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.
[69] B. Coiffier,et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. , 2008, Leukemia research.
[70] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[71] O. Silvennoinen,et al. Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.
[72] E. Reddy,et al. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation , 1998, Oncogene.
[73] C. Schindler,et al. Cytokines and STAT signaling. , 2000, Advances in pharmacology.
[74] M. Fellous,et al. A protein tyrosine kinase in the interferon α β signaling pathway , 1992, Cell.
[75] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[76] S. Pestka,et al. Other Kinases Can Substitute for Jak2 in Signal Transduction by Interferon-γ* , 1996, The Journal of Biological Chemistry.
[77] R. Hoffman,et al. Myeloproliferative neoplasms: new translational therapies. , 2010, The Mount Sinai journal of medicine, New York.
[78] J. Aster,et al. Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.
[79] P. Murray. The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.
[80] F. Dong,et al. Severe congenital neutropenia terminating in acute myeloid leukemia: disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene. , 1996, Leukemia research.
[81] G. Mills,et al. Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[82] E. Reddy,et al. Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. , 2010, Bioorganic & medicinal chemistry.
[83] J. Thompson,et al. Using CLUSTAL for multiple sequence alignments. , 1996, Methods in enzymology.
[84] C. Copie-Bergman,et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma , 2006, Leukemia.
[85] J. Burnside,et al. Computational and functional analysis of the putative SH2 domain in Janus Kinases. , 2000, Biochemical and biophysical research communications.
[86] Tai-Sung Lee,et al. Mechanisms of constitutive activation of Janus kinase 2‐V617F revealed at the atomic level through molecular dynamics simulations , 2009, Cancer.
[87] H. Kreipe,et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. , 2007, Blood.
[88] V. Markovtsov,et al. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases , 2010, International journal of hematology.
[89] Stephanie Kreis,et al. Jaks and cytokine receptors--an intimate relationship. , 2006, Biochemical pharmacology.
[90] S. Kajigaya,et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor , 2006, Proceedings of the National Academy of Sciences.
[91] J. Darnell,et al. Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. , 2006, Genes & development.
[92] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[93] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[94] M. Fellous,et al. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[95] R. Ravazzolo,et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. , 2008, Cancer Genetics and Cytogenetics.
[96] R. Jove,et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.
[97] T. Matsuda,et al. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 , 2006, The EMBO journal.
[98] A. Tefferi. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices , 2010, Leukemia & lymphoma.
[99] J. Roberts,et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. , 2001, Molecular cell.
[100] Mauno Vihinen,et al. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. , 2003, Molecular biology of the cell.
[101] S. Lane,et al. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR‐JAK2 fusion , 2008, British journal of haematology.
[102] M. König,et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia , 2009, Leukemia.
[103] J. Darnell,et al. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. , 1995, Genes & development.
[104] M. Goldsmith,et al. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation , 1997, Current Biology.
[105] A. Ganser,et al. A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. , 1994, The Journal of biological chemistry.
[106] S. Pestka,et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses , 1997, Molecular and cellular biology.
[107] J. Aster,et al. Novel SSBP2‐JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia , 2008, Genes, chromosomes & cancer.
[108] A. Andres,et al. JAK2, a third member of the JAK family of protein tyrosine kinases. , 1992, Oncogene.
[109] F. Johnson,et al. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. , 2009, Cancer research.
[110] K. Arai,et al. Cytokine receptors and signal transduction. , 2005, Annual review of immunology.
[111] Y. Tan,et al. Activation and association of Stat3 with Src in v-Src-transformed cell lines , 1996, Molecular and cellular biology.
[112] D. Levy,et al. JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.
[113] L. Sanders,et al. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[114] J. Johnston,et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[115] J. Prchal,et al. JAK2 kinase inhibitors and myeloproliferative disorders , 2010, Current opinion in hematology.
[116] J. Ihle,et al. Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. , 2008, Cellular signalling.
[117] Massimo Gadina,et al. Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.
[118] A. Krämer. JAK2-V617F and BCR-ABL--double jeopardy? , 2008, Leukemia research.
[119] A. Tefferi,et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera , 2007, Leukemia.
[120] B. Calabretta,et al. Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis , 1999, The Journal of Experimental Medicine.
[121] K. Inokuchi,et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia , 2007, Leukemia.
[122] I. Kerr,et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop , 1997, Molecular and cellular biology.